19 unknown. 19 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 19 | Unknown 19 |
| Phase 2 | 7 | Unknown 7 |
Follow Glomerulonephritis: new trials by email Literature Review of Glomerulonephritis trials Research Report on Glomerulonephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Finerenone in IgA Nephropathy Finerenone, Placebo - IgA Nephropathy | Phase 3 | Unknown | Zhejiang University | 120 | 2024-10-08 | 2024-08-30 |
| Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus Nephritis Methylprednisolone Injectable Suspension, Belimumab Injection, Immunosuppressive Agents - Lupus Nephritis, Remission | Phase 3 | Unknown | Nanjing University School of Medicine | 15 | 2023-04-01 | 2023-05-18 |
| Study of Telitacicept in Patients With Refractory IgA Nephropathy Telitacicept - IgA Nephropathy | Phase 2 / Phase 3 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 40 | 2023-03-01 | 2023-02-24 |
| The Study of Comparing the Efficacy and Safety of Human Umbilical Cord MSCs and Low-dose IL-2 in the Treatment of LN Human umbilical cord mesenchymal stem cells, Interleukin-2 - Systemic Lupus Erythematosus, Lupus Nephritis | Phase 3 | Unknown | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 40 | 2022-10-01 | 2022-11-30 |
| Efficiency of Use of Baracetinib in Treatment of Lupus Nephritis Anti JAK1,2, Cyclophosphamid - Lupus Nephritis | Phase 3 | Unknown | Assiut University | 60 | 2022-06-01 | 2023-01-04 |
| Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis Sirolimus - Lupus Nephritis, Immunosuppression | Phase 2 / Phase 3 | Unknown | Peking Union Medical College Hospital | 20 | 2021-06-30 | 2021-05-19 |
| Steroids Therapy in IgA Nephropathy With Crescents Methylprednisolone - IgA Nephropathy | Phase 3 | Unknown | Sixth Affiliated Hospital, Sun Yat-sen University | 200 | 2021-05-24 | 2021-06-04 |
| Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children Dexamethasone Oral, Placebo - Urinary Tract Infections in Children, Dexamethasone | Phase 3 | Unknown | Hamad Medical Corporation | 120 | 2021-03-03 | 2023-07-25 |
| Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD The Yi-Qi-Qing-Jie herbal compound, Immunosuppressants, Optimized Supportive Care - IgA Nephropathy at High Risk of Developing ESRD | Phase 2 / Phase 3 | Unknown | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | 60 | 2019-07-04 | 2024-09-25 |
| Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome Rituximab, Prednisone - Idiopathic Nephrotic Syndrome, Minimal Change Disease | Phase 3 | Unknown | Radboud University Medical Center | 40 | 2018-08-22 | 2018-08-27 |
| Beginning of Effective and Safe Treatment in Immunoglobulin A-1 Nephropathy-1 Losartan group, Placebo group - Glomerulonephritis, Immunoglobulin A (IgA) | Phase 3 | Unknown | Ewha Womans University | 174 | 2018-01-30 | 2017-11-30 |
| Effect of Rituximab in Treatment of Membranoproliferative Glomerulonephritis Rituximab, Cyclosporin - Membranoproliferative Glomerulonephritis | Phase 3 | Unknown | Assiut University | 30 | 2017-07-01 | 2017-06-16 |
| Valproic Acid for Idiopathic Nephrotic Syndrome Valproic Acid - Idiopathic Nephrotic Syndrome, Focal Segmental Glomerulosclerosis | Phase 2 / Phase 3 | Unknown | Universitair Ziekenhuis Brussel | 15 | 2016-10-01 | 2017-06-20 |
| Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy Prednisolone, Reh-acteoside - IGA Nephropathy | Phase 2 / Phase 3 | Unknown | Sun Yat-sen University | 75 | 2016-05-01 | 2016-02-02 |
| ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study ACTHAR Gel (adrenocorticotropic hormone) - Sarcoidosis, Hypercalcemia Due to Sarcoidosis | Phase 2 / Phase 3 | Unknown | Albany Medical College | 10 | 2015-02-01 | 2015-01-26 |
| RING - Rituximab for Lupus Nephritis With Remission as a Goal RTX infusions, Standard of Care - Lupus Nephritis | Phase 3 | Unknown | Frédéric A. Houssiau, MD, PhD | 194 | 2014-11-01 | 2015-05-28 |
| Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f. Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH), Mycophenolate mofetil (MMF) - IgA Nephropathy | Phase 3 | Unknown | Second Xiangya Hospital of Central South University | 300 | 2014-06-01 | 2014-07-11 |
| Efficacy and Safety of Tripterygium Wilfordii in Patients With Lupus Nephritis Tripterygium wilfordii Hook F, Cyclophosphamide, GC - Nephritis, Lupus | Phase 2 / Phase 3 | Unknown | Peking Union Medical College Hospital | 130 | 2012-07-01 | 2012-07-23 |
| Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy Rituximab, Methylprednisolone, Cyclophosphamide - Glomerulonephritis, Membranous | Phase 3 | Unknown | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 76 | 2012-01-01 | 2019-05-20 |
Glomerulonephritis, IGA (6) · Lupus Nephritis (6) · Glomerulosclerosis, Focal Segmental (2) · Nephrosis, Lipoid (2) · Proteinuria (2) · Disease Progression (1) · Glomerulonephritis, Membranoproliferative (1) · Glomerulonephritis, Membranous (1) · Hypercalcemia (1) · Hypercalciuria (1) · Kidney Diseases (1) · Kidney Failure, Chronic (1) · Lupus Erythematosus, Systemic (1) · Nephritis, Interstitial (1)
Female Urogenital Diseases (19) · Female Urogenital Diseases and Pregnancy Complications (19) · Male Urogenital Diseases (19) · Nephritis (19) · Urogenital Diseases (19) · Urologic Diseases (19) · Kidney Diseases (18) · Immune System Diseases (15) · Autoimmune Diseases (13) · Connective Tissue Diseases (6) · Skin and Connective Tissue Diseases (6) · Lupus Erythematosus, Systemic (5) · Pathological Conditions, Signs and Symptoms (4) · Disease Attributes (3)
Cyclophosphamide (4) · Prednisolone (3) · Rituximab (3) · Immunosuppressive Agents (2) · Methylprednisolone (2) · Prednisone (2) · Adrenal Cortex Hormones (1) · Adrenocorticotropic Hormone (1) · Cyclosporine (1) · Dexamethasone (1) · Interleukin-2 (1) · Losartan (1) · Methylprednisolone Hemisuccinate (1) · Mycophenolic Acid (1) · Sirolimus (1)
Assiut University (2) · Peking Union Medical College Hospital (2) · Albany Medical College (1) · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (1) · Ewha Womans University (1) · Frédéric A. Houssiau, MD, PhD (1) · Guang'anmen Hospital of China Academy of Chinese Medical Sciences (1) · Hamad Medical Corporation (1) · Nanjing University School of Medicine (1) · Radboud University Medical Center (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Second Xiangya Hospital of Central South University (1) · Sixth Affiliated Hospital, Sun Yat-sen University (1) · Sun Yat-sen University (1) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1)
China (8) · Belgium (2) · Egypt (1) · Italy (1) · Netherlands (1) · Qatar (1) · United States (1)
Cheng Zhao, Doctor (1) · Dong-Ryeol Ryu, Professor (1) · Fengchun Zhang, MD (1) · Huayong Zhang, Doctor (1) · Jack F Wetzels, MD, PhD (1) · Jeroen K Deegens, MD,PhD (1) · Jie Wang (1) · Jun Liang, Doctor (1) · Lihui Wen, Doctor (1) · Linyu Geng, Doctor (1) · Mahmoud Alhandi Omar Helal (1) · Manal M Hassanien, Md (1) · Marc A Judson, MD (1)
PMID 38299639, PMID 10093981, PMID 10676716, PMID 11877568, PMID 14694168, PMID 23782179, PMID 26630142, PMID 28341274, PMID 28763548, PMID 31806605, PMID 31907076, PMID 33649098, PMID 34778952, PMID 35224732, PMID 35230699, PMID 38864363